ANDA 91444, held by Hikma. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 91444 (Azelastine Hydrochloride), held by Hikma, was first approved by FDA on Oct 24, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 24, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.137MG/SPRAY · spray, metered;nasal | Azelastine Hydrochloride | Discontinued |
| May 17, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 24, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters